Project Grant R01AR088178
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $421K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $623,286 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate hypoxia-driven NUDT21-mediated alternative polyadenylation in lung and skin fibrosis associated with systemic sclerosis. The project, designated R01AR087804, examines how tissue hypoxia—driven by Raynaud's phenomenon and...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $172,560 to The Trustees of Columbia University in the City of New York on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research on the role of SAP-positive T cells in lupus nephritis, investigating immune mechanisms that initiate and perpetuate kidney inflammation in lupus. The research uses single-cell RNA sequencing with T-cell...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $165,240 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds research applying systems immunology approaches to characterize regulatory T cell (Treg) dysfunction in lupus and across multiple autoimmune conditions. The research leverages an existing integrated dataset of 3.5 million...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Houston System $667,276 in project grant funding on May 20, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds investigation into gene-environment triggers and proteomic pathways that mediate anti-nuclear autoimmunity and systemic rheumatic disease development. The research dissects genetic loci, environmental exposures, gene-by-environment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $156,000 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates pulmonary arterial hypertension susceptibility in systemic sclerosis patients carrying the DNASE1L3 R206C genetic variant. Aim 1 will assess the impact of chronic DNASE1L3 deficiency on the pulmonary vasculature in mice...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Yale University $170,964 on May 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), a Project Grant supporting a five-year career development award (K08AR086982) in dermatology and physician-scientist training. The award funds research into retroelement-mediated mechanisms of systemic lupus erythematosus, a highly morbid autoimmune disease affecting over 200,000 patients...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded National Jewish Health $388,025 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop novel murine and human models defining the role of aberrant T cell subsets in scleroderma pulmonary fibrosis. The recipient will adapt the sclerodermatous graft versus host disease (SCGVHD) murine model of systemic sclerosis to increase lung disease involvement...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Virginia $377,506 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the modulation of efferocytosis in systemic sclerosis. The project examines how the clearance of apoptotic cells—a physiological process that maintains tissue homeostasis and promotes wound healing—intersects with the development and progression of systemic...
- The National Institute of Allergy and Infectious Diseases awarded The University of Texas Southwestern Medical Center $249,000 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, a Project Grant (R21AI199205), funds research into autoreactive T cell and B cell interactions in systemic lupus erythematosus, with work performed in Dallas, Texas through May 31, 2028. The research examines how autoreactive CD4+ T cells and CD8+ T cells interact...
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...